Health Care [ 6/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia.
The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients.
It also developing Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease.
The company is also developing Entinostat.
It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -1.10 Decreased by -10.00% | -0.23 Decreased by -380.56% |
| Nov 5, 24 | -0.98 Decreased by -34.25% | -1.11 Increased by +11.71% |
| Aug 1, 24 | -0.80 Decreased by -25.00% | -0.91 Increased by +12.09% |
| May 8, 24 | -0.85 Decreased by -44.07% | -0.98 Increased by +13.27% |
| Feb 27, 24 | -1.00 Decreased by -61.29% | -0.99 Decreased by -1.01% |
| Nov 2, 23 | -0.73 Decreased by -25.86% | -0.80 Increased by +8.75% |
| Aug 3, 23 | -0.64 Decreased by -3.23% | -0.73 Increased by +12.33% |
| May 8, 23 | -0.59 Increased by +6.35% | -0.60 Increased by +1.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 7.68 M Increased by +1.33 K% | -94.17 M Decreased by -29.94% | Decreased by -1.23 K% Increased by +90.93% |
| Sep 30, 24 | 12.50 M Increased by +N/A% | -84.13 M Decreased by -64.48% | Decreased by -673.01% Decreased by N/A% |
| Jun 30, 24 | 3.50 M Increased by +N/A% | -68.06 M Decreased by -52.56% | Decreased by -1.94 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -72.40 M Decreased by -100.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 536.00 K Increased by +N/A% | -72.47 M Decreased by -99.60% | Decreased by -13.52 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -51.15 M Decreased by -43.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -44.62 M Decreased by -18.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -36.19 M Increased by +3.43% | Decreased by N/A% Decreased by N/A% |